DENVER–(BUSINESS WIRE)–EvoEndo®, Inc. (“EvoEndo”), a medical device company which developed a single use system that allows for unsedated Transnasal Endoscopy (TNE), has announced the completion of an $8.4 million Series A financing round led by founding investor TLP Investment Partners LLC (TLP) and including the Sunshine Charitable Foundation and the Jill and Paul Meister family. Proceeds from the financing will be used to support the initial commercial launch of the EvoEndo® Single-Use Endoscopy System by hiring additional personnel and growing inventory capacity. The company will also deploy the funding to conduct clinical and post-market surveillance studies.
Trending
- GI 2.0: The Playbook | Chapter 8 | The AI-Native GI Practice
- The physician referral black hole is swallowing your growth (BPD)
- Could corporate medicine be on the way out? Inside the new federal bill (MDLinx)
- Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (The New England Journal of Medicine)
- Microbiome Holds Biomarker Predictive of CRC Recurrence (GI & Endoscopy News)
- Are You Performing Second Inspection of the Right Colon? (GI & Endoscopy News)
- The AI Is in the Scope. The Evidence Isn’t. (CDO Trends Weekly)
- Updated Diagnostic Criteria for Acute Severe Ulcerative Colitis (Medscape)
